Clinical Trials
20 trialsNCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT06575725 2024-11-21
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT04231526 2024-07-31
Pembrolizumab in Early Stage Colon Cancer
University of Chicago
Phase 2 Withdrawn
NCT05900648 2024-04-29
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05178576 2022-11-04
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
NSABP Foundation Inc
Phase 2 Withdrawn
NCT03661047 2021-11-17
OMICC
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT00388700 2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT00002664 2017-07-13
Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer
George Washington University
Phase 2 Withdrawn
NCT01095523 2017-07-02
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT01270438 2017-04-04
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02046538 2017-01-25
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT00571740 2016-07-06
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT02235324 2015-05-06
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
University of Southern California
Phase 2 Withdrawn
NCT00003786 2014-03-07
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
University of Chicago
Phase 2 Withdrawn
NCT00003486 2013-07-10
Antineoplaston Therapy in Treating Patients With Colon Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00766220 2013-01-03
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase 2 Withdrawn